Navigation Links
Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
Date:8/5/2013

bo-controlled, multiple-dose study in patients with RA who had chronically elevated CRP.  In this study, 51 patients received 100 mg, 200 mg or 400 mg dose of ISIS-CRPRx or placebo for 12 weeks.  Patients in the study treated with ISIS-CRPRx achieved substantial, dose-dependent reductions in CRP early in treatment that were prolonged through the treatment process.  Patients also experienced improvements in the signs and symptoms of RA, as measured by ACR20 and ACR50 scores.  These improvements correlated with reductions in CRP, but were not sufficiently greater than improvements observed in the placebo groups to justify further development of ISIS-CRPRx for RA. 

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS-CRPRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
2. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
3. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
4. AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
5. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
6. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
7. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
8. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
10. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
11. Avion Pharmaceuticals, LLC, receives top accolades for trade and marketing achievements at the 11th Annual American Business Awards (The "Stevie Awards")
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Healthcare and,Laboratory Corporation of America(R) Holdings (LabCorp(R)) ... agreement to discuss future,possibilities to co-develop new ... diagnostics, metabolic syndrome, oncology and diabetes. Under ... new tests that,could make the biggest impact ...
... of the American Pain Society ... ... sustained pain relief from diabetic neuropathic pain (DNP),compared to placebo-treated patients, according ... (APS) in Tampa, Fla., "This is the first placebo-controlled trial of ...
Cached Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4
(Date:4/23/2014)... proliferation of endogenous neural precursor cells cannot alone ... From the perspective of neural plasticity, Dr. Yun ... China observed the effects of functional electrical stimulation ... expression of basic fibroblast growth factor and epidermal ... infarct side. The researchers found that functional electrical ...
(Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
(Date:4/22/2014)... primary care for low-income patients may ease the ... while improving patient health, researchers have concluded. , ... clinics that avoid costs associated with insurance administration ... admission rates and emergency room visits, according to ... , The researchers estimated that the major ...
(Date:4/22/2014)... risk of pregnancy among women using a newer method ... 10 times greater over a 10-year period than using ... researchers at Yale University and UC Davis has found. ... Contraception , the study found the higher risk ... the brand name Essure. , "This study provides ...
(Date:4/22/2014)... Johns Hopkins scientists have found a way to block ... development of atherosclerosis, the main cause of heart attacks ... humans. The condition develops when fat builds inside blood ... hardened, greatly reducing their ability to feed oxygen-rich blood ... a series of experiments, described April 7 in the ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... influenza testing is associated with reductions in the use ... ,The study was posted online today that ... of Archives of Internal Medicine, one of the JAMA/Archives ... speed at which influenza and other viral diseases are ...
... stress and depression,// may be associated with higher ... in turn are related to an increased risk for ... 22 issue of Archives of Internal Medicine, one of ... studies have linked psychosocial characteristics with cardiovascular disease and ...
... Union after a break of six months. Officials from Hungary ... holding of 3000 geese, and the death of 40 geese. The ... has been confirmed as the deadly H5N1 strain, samples are being ... measures are on to control the spread. A protection zone of ...
... Is the everyday talk of HIV/AIDS falling on deaf ears? ‘Careless’ ... today,// who appear to be completely in-charge of their lives, yet ... ,A new survey has shown that, nearly three out of ... getting HIV. , ,The Body Shop and MTV got ...
... history of abuse by intimate partners have significantly higher ... history of such abuse, according to a study conducted ... ,The higher costs and utilization continued long after the ... University of Washington (UW), and the Harborview Injury Prevention ...
... is how some passengers describe it.// , ... who were infected with a stomach flu-causing bug; norovirus aboard ... , This virus causes a contagious gastric illness, gastroenteritis that ... , The liner’s owner Cunard Line notified ...
Cached Medicine News:Health News:Rapid Flu Testing Decreases Antibiotic Use in Hospitalized Adults 2Health News:Psychosocial Factors Associated With Higher Levels of Inflammatory Markers 2Health News:Fowl Fall in Hungary-Bird Flu Strikes 2Health News:Health Care Costs - Significant for Abused Women 2
Codman Hakim Programmable micro offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often change over the course of...
Codman Hakim Programmable valve cylindrical with PrechamberInline offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition wi...
... V is a low viscosity bone cement, ... vertebroplasty. The bone cement is injected into ... Osteopal V is used for the augmentation ... zirconium dioxide is included in the cement ...
Leadpoint Micro-Electrode Recording...
Medicine Products: